发明名称 RBM3 in bladder cancer
摘要 The present disclosure relates, in one of its aspects, to a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: a) evaluating an amount of RBM3 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group.
申请公布号 AU2012257798(A1) 申请公布日期 2013.11.14
申请号 AU20120257798 申请日期 2012.05.11
申请人 ATLAS ANTIBODIES AB 发明人 EBERHARD, JAKOB;JIRSTROM, KARIN
分类号 C07K14/47;C07K16/00;G01N33/574 主分类号 C07K14/47
代理机构 代理人
主权项
地址